Deutsch English Espaniol

Curriculum vitae
Prof. Dr. rer. nat. Burkhard Hermann Brandt

Name Burkhard Hermann Brandt
Date of Birth July 13th, 1957
e-mail brandt@indivicon.org
1976 - 1982 Westfälische Wilhelms-Universität Münster, faculty: Chemistry (Diplomstudiengang),academic degree: Diplom-Chemiker
1982 - 1985 Research Group of Prof. Klemer/Prof. Micheel; Department of Organic Chemistry; Subject: Precursors of Antibiotics and Cytostatics (Stereoselektive Funktionalisierung von Kohlenhydraten), degree: Dr. rer. nat..
1985 Scientific faculty at the Institute for Clinical Chemistry and Laboratory Medicine, continuing education on Clinical Chemistry and Molecular Diagnostics
1989 Assistant Professor (Wissenschaftlicher Hochschulassistent, C1) at the Institute for Clinical Chemistry and Laboratory Medicine; Consultant ("Oberassistent")
1991 Establishment of the Research Group Oncological Chemistry at the Institute for Clinical Chemistry and Laboratory Medicine
1992 Honorary Assistant Professor for Oncological Chemistry at Institute for Immunology at the Universität Witten/Herdecke
1993 Clinical Chemist, accreditation by the German Society for Clinical Chemistry (Deutsche Gesellschaft für Klinische Chemie)
1998 Elected member of the European Organization on Research and Treatment of Cancer (EORTC) Receptor and Biomarker Study Group
1999 Qualification to teach in higher education (Habilitation und venia legendi) for Clinical Chemistry; Tenure position (BAT-analog C3-Prof.)
1999 Establishment of a unit for high through-put genetic analysis and a molecular diagnostics branch (robotics, sequencing by capillary electrophoresis, real-time PCR)
2000 Winner of the "BioChip-Initiative" of the State of Nordrhein-Westfalen
2002 AIO-Scientific award for clinical tumor research (Wissenschaftpreis der Arbeitsgemeinschaft für internistische Onkologie in der Deutschen Krebsgesellschaft auf dem Gebiet der klinischen Tumorforschung
2003 Professor (apl. Prof.)
2004 Professor for Tumor Biology (C3) at the Institut for Tumor Biology, University of Hamburg
2005 Winner of the "Innovationswettbewerb Fortschritte der Medizintechnik 2005“" of the German Government, Department of Research and Education
2005 Certification by EC4 Register Committee "Eurpean Specialist in Clinical Chemistry and Laboratory Medicine"

Original publications since 2000

  1. Kemming D, Vogt U, Tidow N, Schlotter CM, Burger H, Helms MW, Korsching E, Granetzny A, Boseila A, Hillejan L, Marra A, Ergonenc Y, Adiguzel H, Brandt B. Whole genome expression analysis for biologic rational pathway modeling : application in cancer prognosis and therapy prediction. Mol Diagn Ther. 2006;10(5):271-80.
  2. Schmidt H, DeAngelis G, Eltze E, Gockel I, Semjonow A, Brandt B. Asynchronous growth of prostate cancer is reflected by circulating tumor cells delivered from distinct, even small foci, harboring loss of heterozygosity of the PTEN gene. Cancer Res. 2006 Sep 15;66(18):8959-65.
  3. Mooren FC, Lechtermann A, Fobker M, Brandt B, Sorg C, Volker K, Nacken W. The response of the novel pro-inflammatory molecules S100A8/A9 to exercise. Int J Sports Med. 2006 Sep;27(9):751-8.
  4. Korsching E, Agelopolous K, Schmidt H, Buchroth I, Gosheger G, Wulfing P, Boecker W, Brandt B, Buerger H. Improvements in the analysis strategy make single nucleotide polymorphism analysis a powerful tool in the detection and characterization of amplified chromosomal regions in human tumors. Pathobiology. 2006;73(1):18-25.
  5. Mikesch JH, Buerger H, Simon R, Brandt B. Decay-accelerating factor (CD55): a versatile acting molecule in human malignancies. Biochim Biophys Acta – Reviews on Cancer. 2006 Aug;1766(1):42-52.
  6. Welnicka-Jaskiewicz M, Zaczek A, Brandt B, Bielawski KP, Jaskiewicz J, Konopa K, Jassem J. (CA)n microsatellite polymorphism of ERBB-1 in breast cancer. Eur J Cancer. 2006 Aug;42(12):1698-701.
  7. Helms MW, Brandt BH, Contag CH. Options for visualizing metastatic disease in the living body. Contrib Microbiol. 2006;13:209-31.
  8. Wulfing P, Borchard J, Buerger H, Heidl S, Zanker KS, Kiesel L, Brandt B. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res. 2006 Mar 15;12(6):1715-20.
  9. Kersting C, Packeisen J, Leidinger B, Brandt B, von Wasielewski R, Winkelmann W, van Diest PJ, Gosheger G, Buerger H. Pitfalls in immunohistochemical assessment of EGFR expression in soft tissue sarcomas. J Clin Pathol. 2006 Jun;59(6):585-90.
  10. Fillies T, Werkmeister R, Packeisen J, Brandt B, Morin P, Weingart D, Joos U, Buerger H. Cytokeratin 8/18 expression indicates a poor prognosis in squamous cell carcinomas of the oral cavity. BMC Cancer. 2006 Jan 13;6:10.
  11. Brandt B, Kemming D, Packeisen J, Simon R, Helms M, Feldmann U, Matuschek A, Kersting C, Hinrichs B, Bidart JM, Bellet D, Bartkowiak K, Dankbar N, Dittmar T, Sauter G, Boecker W, Buerger H. Expression of early placenta insulin-like growth factor in breast cancer cells provides an autocrine loop that predominantly enhances invasiveness and motility. Endocr Relat Cancer. 2005 Dec;12(4):823-37.
  12. Kersting C, Kuijper A, Schmidt H, Packeisen J, Liedtke C, Tidow N, Gustmann C, Hinrichs B, Wulfing P, Tio J, Boecker W, van Diest P, Brandt B, Buerger H. Amplifications of the epidermal growth factor receptor gene (egfr) are common in phyllodes tumors of the breast and are associated with tumor progression. Lab Invest. 2006 Jan;86(1):54-61.
  13. Bielawski KP, Klos P, Welnicka-Jaskiewicz M, Tidow M, Brandt B, Falkiewicz B, Zaczek A. An epidermal growth factor receptor intron 1 polymorphism in healthy women in Poland. Int J Biol Markers. 2005 Jul-Sep;20(3):184-8.
  14. Packeisen J, Nakachi K, Boecker W, Brandt B, Buerger H. Cytogenetic differences in breast cancer samples between German and Japanese patients. J Clin Pathol. 2005 Oct;58(10):1101-3.
  15. Palm D, Lang K, Brandt B, Zaenker KS, Entschladen F. In vitro and in vivo imaging of cell migration: two interdepending methods to unravel metastasis formation. Semin Cancer Biol. 2005 Oct;15(5):396-404. Review.
  16. Brandt B, Heyder C, Gloria-Maercker E, Hatzmann W, Rotger A, Kemming D, Zanker KS, Entschladen F, Dittmar T. 3D-extravasation model -- selection of highly motile and metastatic cancer cells. Semin Cancer Biol. 2005 Oct;15(5):387-95. Review.
  17. Fillies T, Werkmeister R, van Diest PJ, Brandt B, Joos U, Buerger H. HIF1-alpha overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor. BMC Cancer. 2005 Jul 21;5:84.
  18. Zaczek A, Brandt B, Bielawski KP. The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches. Histol Histopathol. 2005 Jul;20(3):1005-15.
  19. Fillies T, Buerger H, Gaertner C, August C, Brandt B, Joos U, Werkmeister R. Catenin expression in T1/2 carcinomas of the floor of the mouth. Int J Oral Maxillofac Surg. 2005 Dec;34(8):907-11.
  20. Korsching E, Packeisen J, Liedtke C, Hungermann D, Wulfing P, van Diest PJ, Brandt B, Boecker W, Buerger H. The origin of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? J Pathol. 2005 Aug;206(4):451-7.
  21. Helms MW, Packeisen J, August C, Schittek B, Boecker W, Brandt BH, Buerger H. First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptor-positive breast cancer. J Pathol. 2005 Jul;206(3):366-76.
  22. Zaczek A, Welnicka-Jaskiewicz M, Buerger H, Brandt BH, Bielawski KP. Modified direct-double-differential PCR for gene dosage quantification of HER2. Oncol Rep. 2005 May;13(5):971-5.
  23. Joosten U, Joist A, Gosheger G, Liljenqvist U, Brandt B, von Eiff C. Effectiveness of hydroxyapatite-vancomycin bone cement in the treatment of Staphylococcus aureus induced chronic osteomyelitis. Biomaterials. 2005 Sep;26(25):5251-8.
  24. Brandt B, Mikesch JH, Simon R, Rotger A, Kemming D, Schier K, Sauter G, Burger H. Selective expression of a splice variant of decay-accelerating factor in c-erbB-2-positive mammary carcinoma cells showing increased transendothelial invasiveness. Biochem Biophys Res Commun. 2005 Apr 1;329(1):318-
  25. Bettendorf O, Schmidt H, Eltze E, Gockel I, Semjonow A, Burger H, Bocker W, Brandt B. Cytogenetic changes and loss of heterozygosity in atypical adenomatous hyperplasia, in carcinoma of the prostate and in non-neoplastic prostate tissue using comparative genomic hybridization and multiplex-PCR. Int J Oncol. 2005 Jan;26(1):267-74.
  26. Schmidt H, De Angelis G, Bettendorf O, Eltze E, Semjonow A, Knichwitz G, Brandt B. Frequent detection and immunophenotyping of prostate-derived cell clusters in the peripheral blood of prostate cancer patients. Int J Biol Markers. 2004 Apr-Jun;19(2):93-9.
  27. Buerger H, Packeisen J, Boecker A, Tidow N, Kersting C, Bielawski K, Isola J, Yatabe Y, Nakachi K, Boecker W, Brandt B. Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence--first results of an inter-ethnic breast cancer study. J Pathol. 2004 May;203(1):545-50.
  28. Korsching E, Packeisen J, Helms MW, Kersting C, Voss R, van Diest PJ, Brandt B, van der Wall E, Boecker W, Burger H. Deciphering a subgroup of breast carcinomas with putative progression of grade during carcinogenesis revealed by comparative genomic hybridisation (CGH) and immunohistochemistry. Br J Cancer. 2004 Apr 5;90(7):1422-8.
  29. Joosten U, Joist A, Frebel T, Brandt B, Diederichs S, von Eiff C. Evaluation of an in situ setting injectable calcium phosphate as a new carrier material for gentamicin in the treatment of chronic osteomyelitis: studies in vitro and in vivo. Biomaterials. 2004 Aug;25(18):4287-95.
  30. Kersting C, Tidow N, Schmidt H, Liedtke C, Neumann J, Boecker W, van Diest PJ, Brandt B, Buerger H. Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of egfr amplifications despite protein overexpression in invasive breast carcinoma. Lab Invest. 2004 May;84(5):582-7.
  31. Muller-Tidow C, Schwable J, Steffen B, Tidow N, Brandt B, Becker K, Schulze-Bahr E, Halfter H, Vogt U, Metzger R, Schneider PM, Buchner T, Brandts C, Berdel WE, Serve H. High-throughput analysis of genome-wide receptor tyrosine kinase expression in human cancers identifies potential novel drug targets. Clin Cancer Res. 2004 Feb 15;10(4):1241-9.
  32. Brandt B, Hermann S, Straif K, Tidow N, Buerger H, Chang-Claude J. Modification of breast cancer risk in young women by a polymorphic sequence in the egfr gene. Cancer Res. 2004 Jan 1;64(1):7-12.
  33. Katterle Y, Brandt BH, Dowdy SF, Niggemann B, Zanker KS, Dittmar T. Antitumour effects of PLC-gamma1-(SH2)2-TAT fusion proteins on EGFR/c-erbB-2-positive breast cancer cells. Br J Cancer. 2004 Jan 12;90(1):230-5.
  34. Ji P, Diederichs S, Wang W, Boing S, Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, Thomas M, Berdel WE, Serve H, Muller-Tidow C. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene. 2003 Sep 11;22(39):8031-41.
  35. Agelopoulos K, Tidow N, Korsching E, Voss R, Hinrichs B, Brandt B, Boecker W, Buerger H. Molecular cytogenetic investigations of synchronous bilateral breast cancer. J Clin Pathol. 2003 Sep;56(9):660-5.
  36. Keller R, Brandt B, Terpe HJ, Winde G, Foerster EC, Domschke W. Cytology and image cytometry after colonic lavage: a complementary diagnostic tool in patients with ulcerative colitis. Dig Liver Dis. 2003 Jan;35(1):24-31.
  37. Oberpenning F, Hetzel S, Weining C, Brandt B, De Angelis G, Heinecke A, Lein M, Fornara P, Schmid HP, Hertle L, Semjonow A. Semi-quantitative immunochromatographic test for prostate specific antigen in whole blood: tossing the coin to predict prostate cancer? Eur Urol. 2003 May;43(5):478-84.
  38. Tidow N, Boecker A, Schmidt H, Agelopoulos K, Boecker W, Buerger H, Brandt B. Distinct amplification of an untranslated regulatory sequence in the egfr gene contributes to early steps in breast cancer development. Cancer Res. 2003 Mar 15;63(6):1172-8.
  39. Oberpenning F, Weining C, Brandt B, De Angelis G, Heinecke A, Hamm M, Stieber P, Hertle L, Schmid HP, Semjonow A. A new modification of the Chiron ACS assay for total prostate-specific antigen achieves equimolar response characteristics and improves the detection of prostate cancer. Clin Chem Lab Med. 2003 Jan;41(1):90-4.
  40. Oberpenning F, Weining C, Brandt B, De Angelis G, Heinecke A, Hamm M, Stieber P, Hertle L, Schmid HP, Semjonow A. Combining free and total prostate specific antigen assays from different manufacturers: the pitfalls. Eur Urol. 2002 Dec;42(6):577-82; discussion 582.
  41. Brandt BH. Molecular diagnostics of solid malignant tumours. Clin Lab. 2002;48(11-12):605-15.
  42. Korsching E, Packeisen J, Agelopoulos K, Eisenacher M, Voss R, Isola J, van Diest PJ, Brandt B, Boecker W, Buerger H. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest. 2002 Nov;82(11):1525-33.
  43. Dittmar T, Husemann A, Schewe Y, Nofer JR, Niggemann B, Zanker KS, Brandt BH. Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor via EGFR. FASEB J. 2002 Nov;16(13):1823-5.
  44. Bocker W, Moll R, Poremba C, Holland R, Van Diest PJ, Dervan P, Burger H, Wai D, Ina Diallo R, Brandt B, Herbst H, Schmidt A, Lerch MM, Buchwallow IB. Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. Lab Invest. 2002 Jun;82(6):737-46.
  45. Kubens BS, Feldner JC, Brandt B, Zanker KS. Migrating and circulating breast carcinoma cells are within active phases of the cell cycle. Anticancer Res. 2002 Mar-Apr;22(2A):899-903.
  46. Reinmuth N, Brandt B, Semik M, Kunze WP, Achatzy R, Scheld HH, Broermann P, Berdel WE, Macha HN, Thomas M. Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer. Lung Cancer. 2002 Jun;36(3):265-70.
  47. Broermann P, Junker K, Brandt BH, Heinecke A, Freitag L, Klinke F, Berdel WE, Thomas M. Trimodality treatment in Stage III nonsmall cell lung carcinoma: prrognostic impact of K-ras mutations after neoadjuvant therapy. Cancer. 2002 Apr 1;94(7):2055-62.
  48. Brandt B, Roetger A, Bidart JM, Packeisen J, Schier K, Mikesch JH, Kemming D, Boecker W, Yu D, Buerger H. Early placenta insulin-like growth factor (pro-EPIL) is overexpressed and secreted by c-erbB-2-positive cells with high invasion potential. Cancer Res. 2002 Feb 15;62(4):1020-4.
  49. Feldner JC, Brandt BH. Cancer cell motility--on the road from c-erbB-2 receptor steered signaling to actin reorganization. Exp Cell Res. 2002 Jan 15;272(2):93-108. Review.
  50. Buerger H, Schmidt H, Beckmann A, Zanker KS, Boecker W, Brandt B. Genetic characterisation of invasive breast cancer: a comparison of CGH and PCR based multiplex microsatellite analysis. J Clin Pathol. 2001 Nov;54(11):836-40.
  51. Semjonow A, Oberpenning F, Weining C, Schon M, Brandt B, De Angelis G, Heinecke A, Hamm M, Stieber P, Hertle L, Schmid HP. Do modifications of nonequimolar assays for total prostate-specific antigen improve detection of prostate cancer? Clin Chem. 2001 Aug;47(8):1472-5.
  52. Nap M, Brockhoff G, Brandt B, Knuechel R, Leers MP, Schmidt H, De Angelis G, Eltze E, Semjonow A. Flow cytometric DNA and phenotype analysis in pathology. Virchows Arch. 2001 May;438(5):425-32.
  53. Dittmar T, Brandt BH, Lang K, Zaenker KS, Entschladen F. Lessons from tumor and immunocompetent cells. The quantitative engagement of ligand-receptor interactions modulates stop-and-go behavior as well as proliferation. Medicina (B Aires). 2000;60 Suppl 2:27-33.
  54. Brandt BH, Schmidt H, de Angelis G, Zanker KS. Predictive laboratory diagnostics in oncology utilizing blood-borne cancer cells--current best practice and unmet needs. Cancer Lett. 2001 Jan;162 Suppl:S11-S16.
  55. Reinmuth N, Brandt B, Kunze WP, Junker K, Thomas M, Achatzy R, Scheld HH, Semik M. Ploidy, expression of erbB1, erbB2, P53 and amplification of erbB1, erbB2 and erbB3 in non-small cell lung cancer. Eur Respir J. 2000 Nov;16(5):991-6.
  56. Bankfalvi A, Simon R, Brandt B, Burger H, Vollmer I, Dockhorn-Dworniczak B, Lelle RJ, Boecker W. Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use. Histopathology. 2000 Nov;37(5):411-9.
  57. Dittmar T, Schafer F, Brandt BH, Zanker KS. Accelerated assessing of antisense RNA efficacy using a chimeric enhanced green fluorescent protein-antisense RNA-producing vector. Antisense Nucleic Acid Drug Dev. 2000 Oct;10(5):401-8.
  58. Semjonow A, De Angelis G, Oberpenning F, Schmid HP, Brandt B, Hertle L. The clinical impact of different assays for prostate specific antigen. BJU Int. 2000 Sep;86(5):590-7. Review. No abstract available.
  59. Gebhardt F, Burger H, Brandt B. Modulation of EGFR gene transcription by secondary structures, a polymorphic repetitive sequence and mutations--a link between genetics and epigenetics. Histol Histopathol. 2000 Jul;15(3):929-36.
  60. De Angelis G, Brandt B, Schmid HP, Semjonow A. [From antigen to tumor marker. Results of research regarding PSA and its clinical applications] Urologe A. 2000 Jul;39(4):309-12.
  61. Werkmeister R, Brandt B, Joos U. Clinical relevance of erbB-1 and -2 oncogenes in oral carcinomas. Oral Oncol. 2000 Jan;36(1):100-5.
  62. Brandt B, Schmitt H, Feldner JC, Lelle RJ, Semjonow A, Beckmann A. Blood-borne cancer cells--quo vadis? Int J Biol Markers. 2000 Jan-Mar;15(1):111-3.
  63. Gebhardt F, Burger H, Brandt B. Modulation of EGFR gene transcription by a polymorphic repetitive sequence--a link between genetics and epigenetics. Int J Biol Markers. 2000 Jan-Mar;15(1):105-10. Review.
  64. Azemar M, Schmidt M, Arlt F, Kennel P, Brandt B, Papadimitriou A, Groner B, Wels W. Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo. Int J Cancer. 2000 Apr 15;86(2):269-75.
  65. Buerger H, Gebhardt F, Schmidt H, Beckmann A, Hutmacher K, Simon R, Lelle R, Boecker W, Brandt B. Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression. Cancer Res. 2000 Feb 15;60(4):854-7.
  66. Brandt BH, Roetger A, Dittmar T, Nikolai G, Seeling M, Merschjann A, Nofer JR, Dehmer-Moller G, Junker R, Assmann G, Zaenker KS. c-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells. FASEB J. 1999 Nov;13(14):1939-49.
  67. Gebhardt F, Zanker KS, Brandt B. Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem. 1999 May 7;274(19):13176-80.
  68. Roetger A, Merschjann A, Dittmar T, Jackisch C, Barnekow A, Brandt B. Selection of potentially metastatic subpopulations expressing c-erbB-2 from breast cancer tissue by use of an extravasation model. Am J Pathol. 1998 Dec;153(6):1797-806.
« Zurück